Literature DB >> 22230434

Immunology of brain tumors.

Patrick Roth1, Günter Eisele, Michael Weller.   

Abstract

Brain tumors of different origin, but notably malignant gliomas, are characterized by their immunosuppressive properties which allow them to escape the host's immune surveillance. The activating immune cell ligands that are expressed by tumor cells, together with potentially immunogenic antigens, are overridden by numerous immune inhibitory signals, with TGF-3 as the master immunosuppressive molecule (Figure 4.1).The ongoing investigation of mechanisms of tumor-derived immunosuppression allows for an increasing understanding of brain tumor immunology. Targeting different mechanisms of tumor-derived immunosuppression, such as inhibition of TGF-[, may represent a promising strategy for future immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230434     DOI: 10.1016/B978-0-444-52138-5.00004-9

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  9 in total

Review 1.  Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

Authors:  Patrick Roth; Michael Weller
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

2.  Characterization of the inflammatory response to solid cancer metastases in the human brain.

Authors:  Anna Sophie Berghoff; Hans Lassmann; Matthias Preusser; Romana Höftberger
Journal:  Clin Exp Metastasis       Date:  2012-07-01       Impact factor: 5.150

Review 3.  Dendritic Cell-Targeted Therapies to Treat Neurological Disorders.

Authors:  Asim Hussain; Hamza Rafeeq; Nimra Munir; Zara Jabeen; Nadia Afsheen; Khalil Ur Rehman; Muhammad Bilal; Hafiz M N Iqbal
Journal:  Mol Neurobiol       Date:  2021-11-06       Impact factor: 5.590

4.  ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.

Authors:  Na Tosha N Gatson; Shiao-Pei S Weathers; John F de Groot
Journal:  CNS Oncol       Date:  2015-12-15

Review 5.  Glia and methylmercury neurotoxicity.

Authors:  Mingwei Ni; Xin Li; João B T Rocha; Marcelo Farina; Michael Aschner
Journal:  J Toxicol Environ Health A       Date:  2012

6.  MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.

Authors:  Paula Codo; Michael Weller; Gunter Meister; Emese Szabo; Alexander Steinle; Marietta Wolter; Guido Reifenberger; Patrick Roth
Journal:  Oncotarget       Date:  2014-09-15

7.  Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.

Authors:  Markus Christmann; Kathrin Diesler; Dragomira Majhen; Christian Steigerwald; Nancy Berte; Halima Freund; Nikolina Stojanović; Bernd Kaina; Maja Osmak; Andreja Ambriović-Ristov; Maja T Tomicic
Journal:  Oncotarget       Date:  2017-04-25

8.  Antibodies Against Hypothalamus and Pituitary Gland in Childhood-Onset Brain Tumors and Pituitary Dysfunction.

Authors:  Giuseppa Patti; Erika Calandra; Annamaria De Bellis; Annalisa Gallizia; Marco Crocco; Flavia Napoli; Anna Maria Elsa Allegri; Hanan F Thiabat; Giuseppe Bellastella; Maria Ida Maiorino; Maria Luisa Garrè; Stefano Parodi; Mohamad Maghnie; Natascia di Iorgi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-18       Impact factor: 5.555

9.  Immune Infiltration Analysis with the CIBERSORT Method in Lung Cancer.

Authors:  Meng Guan; Yan Jiao; Lili Zhou
Journal:  Dis Markers       Date:  2022-03-18       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.